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ABSTRACT
Aims/Introduction: Taste receptors, T1rs and T2rs, and the taste-selective G-protein, a-
gustducin, are expressed outside the taste-sensing system, such as enteroendocrine L cells.
Here, we examined whether a-gustducin also affects nutrition sensing and insulin secre-
tion by pancreatic b-cells.
Materials and Methods: The expression of a-gustducin and taste receptors was eval-
uated in b-cell lines, and in rat and mouse islets either by quantitative polymerase chain
reaction or fluorescence immunostaining. The effects of a-gustducin knockdown on insu-
lin secretion and on cyclic adenosine monophosphate and intracellular Ca2+ levels in rat
INS-1 cells were estimated. Sucralose (taste receptor agonist)-induced insulin secretion was
investigated in INS-1 cells with a-gustducin suppression and in islets from mouse disease
models.
Results: The expression of Tas1r3 and a-gustducin was confirmed in b-cell lines and
pancreatic islets. Basal levels of cyclic adenosine monophosphate, intracellular calcium and
insulin secretion were significantly enhanced with a-gustducin knockdown in INS-1 cells.
The expression of a-gustducin was decreased in high-fat diet-fed mice and in diabetic
db/db mice. Sucralose-induced insulin secretion was not attenuated in INS-1 cells with a-
gustducin knockdown or in mouse islets with decreased expression of a-gustducin.
Conclusions: a-Gustducin is involved in the regulation of cyclic adenosine monophos-
phate, intracellular calcium levels and insulin secretion in pancreatic b-cells in a manner
independent of taste receptor signaling. a-Gustducin might play a novel role in b-cell
physiology and the development of type 2 diabetes.
INTRODUCTION
Taste cells aid in the detection of nutrients, such as sugars,
sweeteners and umami compounds, through heterodimers of
type 1 taste receptor subunits (T1rs). T1r2 and T1r3 form a
heterodimer in taste cells, which responds widely to sweetness
elicited by compounds, such as glucose, sucrose and artificial
sweeteners1,2. A heterodimer of T1r1 and T1r3 recognizes
umami compounds, such as glutamate, monosodium glutamate
and inosinic acid1,3. Sweet and bitter compounds bind to and
activate specific G-protein coupled receptors that interact with
G-proteins, such as a-gustducin4.
a-Gustducin is also expressed in brush cells of the stomach,
duodenum and pancreatic duct in rats5–7. It has been reported
that T1rs, T2rs and a-gustducin are expressed in intestinal
endocrine L cells, and are involved in glucagon-like peptide-1
(GLP-1) secretion signaling in response to glucose8–10. As pan-
creatic b-cells secrete insulin in response to glucose and other
nutrients, taste receptors and/or a-gustducin could also be
implicated in nutrition sensing in these cells. However, just a
few studies have explored the expression and function of these
taste-related molecules in pancreatic b-cells11–14.
In the present study, we focused on the taste signaling-re-
lated molecule, a-gustducin, and examined its role in insulin
secretion by pancreatic b-cells. We examined the expression of
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a-gustducin in rat and mouse islets, and the rat pancreatic
b-cell line INS-1, and investigated the role of a-gustducin in
INS-1 cells. We also examined whether a-gustducin is involved
in the regulation of cyclic adenosine monophosphate (cAMP)
and intracellular calcium levels within these cells.
METHODS
Cell culture
INS-1 cells were cultured in RPMI1640 medium (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen, Carlsbad, CA,
USA), 50 lmol/L 2-mercaptoethanol, 1 mmol/L sodium pyru-
vate, 10 mmol/L HEPES, 100 U/mL penicillin and 100 lg/mL
streptomycin (Invitrogen) at 37°C in a 5% CO2-enriched
atmosphere15. MIN6 cells were gifted by Dr J Miyazaki
(Osaka University, Osaka, Japan). They were cultured at 37°C
in a 5% CO2-enriched atmosphere in Dulbecco’s modified
Eagle’s medium (Sigma-Aldrich) with 15% heat-inactivated
fetal bovine serum (Sigma-Aldrich), 50 lmol/L 2-mercap-
toethanol, 100 U/mL penicillin and 100 lg/mL streptomycin
(Invitrogen).
Animals
Male C57BL/6J mice and male BKS.Cg-+ Leprdb/+ Leprdb/Jcl
(db/db) mice were purchased from CLEA Japan Inc. (Tokyo,
Japan). C57BL/6J mice were maintained under standard condi-
tions and fed with a standard diet (STD; CE-2, 12 kcal%;
CLEA Japan Inc., Tokyo, Japan) ad libitum. At 10 weeks-
of-age, one group of mice of each strain was fed with a high-
fat diet (HFD; D12492, 60 kcal%; Research Diets Inc., New
Brunswick, NJ, USA), whereas other strain- and age-matched
control groups were fed with STD during the experimental per-
iod. All experimental procedures were carried out in accordance
with the guidelines of the animal care and experimentation
committee at the National Center for Global Health and Medi-
cine. Male Wistar rats were purchased from CLEA Japan Inc.
Islet isolation and batch incubation
Islets of Langerhans were isolated from the pancreas of 11-
week-old male C57BL/6J mice and 26-week-old STD mice,
HFD mice16 or 8-week-old Wistar rat17 through collagenase
digestion. The isolated islets were then washed and preincu-
bated at 37°C for 30 min in Krebs–Ringer bicarbonate (KRB)
buffer (129 mmol/L NaCl, 4.8 mmol/L KCl, 1.2 mmol/L
MgSO4, 1.2 mmol/L KH2PO4, 2 mmol/L CaCl2, 5 mmol/L
NaHCO3, 10 mmol/L HEPES (pH 7.4) and 0.1% bovine serum
albumin [BSA])18. The islets were incubated in buffer contain-
ing 2.8 mmol/L glucose + 10 mmol/L sucralose, 2.8 mmol/L
glucose + 0.1 lmol/L GLP-1 and 16.7 mmol/L glucose for
30 min. Cellular insulin was extracted with acid-ethanol. Insulin
secreted into the Krebs-Ringer-HEPES (KRH) buffer and total
insulin content was measured using the Ultra-Sensitive Mouse
Insulin ELISA Kit (Morinaga Institute of Biological Science
Inc., Yokohama, Japan).
Quantitative polymerase chain reaction primers
TaqMan gene expression assay probes for rat guanine nucleo-
tide-binding protein alpha transducing 3 (Gnat3; a-gust-
ducin), taste receptor type 1 member 1 (Tas1r1), taste receptor
type 1 member 2 (Tas1r2), taste receptor type 1 member 3
(Tas1r3) and b-actin (Actb) were obtained from Thermo
Fisher Scientific (Waltham, MA, USA; catalog numbers
Rn00597619, Rn01516038, Rn01515491, Rn00590759 and
4352931E, respectively). TaqMan gene expression assay probes
for mouse Gnat3 (a-gustducin), Tas1r1, Tas1r2 and Tas1r3
were obtained from Ambion (Mm01165313, Mm00473433,
Mm00499716 and Mm00473459, respectively).
Immunohistochemistry
Pancreata were excised, fixed in 4% paraformaldehyde, embed-
ded in paraffin and immunostained, as described previously19.
Primary antibodies against rabbit anti-a-gustducin (sc395; Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) and guinea pig
anti-insulin (Takara Bio Inc., Shiga, Japan) were used. DyLight
594-conjugated anti-guinea pig immunoglobulin G (1:100) or
fluorescein isothiocyanate-conjugated anti-rabbit (1:100; Jackson
ImmunoResearch, West Grove, PA, USA) were used as sec-
ondary antibodies. TOPRO3 (1:1000) was used to label the
nuclei (Molecular Probes, Eugene, OR, USA). Immunofluores-
cence images were obtained using a Zeiss LSM510 confocal
microscope (Carl Zeiss Co., Tokyo, Japan) in confocal mode.
Immunocytochemistry
INS-1 cells were fixed with 4% (w/v) paraformaldehyde for
15 min, permeabilized with 0.25% (w/v) Triton X-100 in phos-
phate-buffered saline (PBS) for 15 min and immunostained, as
described previously19,20. After blocking with PBS containing
10% (w/v) BSA for 30 min, the cells were incubated overnight
with the primary antibody in PBS containing 3% (w/v) BSA,
washed with PBS and then incubated with secondary antibody in
PBS containing 3% (w/v) BSA for 1 h, followed by washing with
PBS and mounting. Immunofluorescence images were obtained
using a Zeiss LSM510 confocal microscope in confocal mode.
Transfection of small interfering ribonucleic acids
Small interfering ribonucleic acids (siRNA) targeting rat a-
gustducin (2 different siRNA), and a non-targeting negative
control siRNA were obtained from Thermo Fisher Scientific
(Gust siRNA1: s141856, Gust siRNA2: s141857 and AM4642,
respectively).
siRNA was transiently transfected with Lipofectamine 2000
reagent (Invitrogen), according to the manufacturer’s instruc-
tions. a-Gustducin messenger RNA (mRNA) expression was
assayed 48 h after siRNA transfection, and transcriptional silenc-
ing was validated using at least three independent experiments.
RNA preparation and quantitative real-time polymerase chain
reaction
Total RNA was extracted from INS-1 cells or mouse pancreatic
islets using the RNeasy Mini Kit (Qiagen, Cologne, Germany).
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Complementary deoxyribonucleic acid was prepared from 1 lg
of total RNA using reverse transcriptase (SuperScript IITM;
Invitrogen), according to the manufacturer’s instructions. Quan-
titative polymerase chain reaction amplification was carried out
using the TaqMan universal polymerase chain reaction master
mix core reagent kit and analyzed using an ABI Prism 7900
(Applied Biosystems). The mRNA levels were evaluated and
normalized against Actb expression level using the 2–DDCt
method21.
Western blot analysis
Protein fraction of INS-1 cells was extracted using a Subcellular
Protein Fractionation Kit (Thermo Fisher Scientific Inc.). The
protein samples were resolved using 4–20% sodium dodecyl
sulfate polyacrylamide gel electrophoresis, and gels were trans-
ferred to polyvinylidenedifluoride membrane filters (BioRad
Laboratories, Hercules, CA, USA). Western bolt analyses were
carried out using antibodies against a-gustducin (Santa Cruz
Biotechnology), Actb, a-tubulin, lamin A/C (Cell Signaling
Technology, Danvers, MA, USA; #4967, #2144, #2032, respec-
tively) and E-cadherin (BD Transduction Laboratories, Franklin
Lakes, NJ, USA; #610181), and detected using Immobilon Wes-
tern Chemiluminescent HRP Substrate (Millipore Co., Billerica,
MA, USA).
Measurement of insulin level and secretion from INS-1 cells
After the indicated culture periods, INS-1 cells were washed with
KRB buffer supplemented with 0.1 mmol/L glucose and 0.5%
BSA, preincubated at 37°C for 30 min in KRB buffer containing
3 mmol/L glucose, and incubated at 37°C for 60 min with the
indicated concentration of glucose and/or several stimulants. Insu-
lin secreted into the KRB buffer was quantified using the Mouse
Insulin ELISA KIT (T-Type; AKRIN-011T; Shibayagi, Gunma,
Japan). Cellular insulin was extracted using acid-ethanol overnight
at 4 °C, and insulin level was determined using enzyme-linked
immunosorbent assay, after dilution.
Measurement of cAMP levels
cAMP levels in INS-1 cells were determined using the cAMP
Biotrak enzyme immunoassay system (GE Healthcare UK Ltd.,
Amersham, UK), according to the manufacturer’s instructions.
Intracellular calcium analysis
Intracellular calcium concentration ([Ca2+]i) in INS-1 cells was
measured with a Calcium kit Fluo-4 (#CS22; Dojindo Molecu-
lar Technologies, Inc., Kumamoto, Japan). INS-1 cells were
placed on a φ35-mm glass bottom culture dish. Growth med-
ium was replaced with loading buffer containing 3 mmol/L glu-
cose and Fluo4-AM, and the culture dish was incubated at
37°C for 1 h. Loading buffer was then replaced with recording
buffer containing 3 mmol/L glucose. The Fluo-4 fluorescent sig-
nal over the INS-1 cell area was detected through excitation at



































































Figure 1 | Expression of taste receptors and a-gustducin (Gust) in islets
and cell lines. (a) The expression of taste receptors, T1r1, T1r2 and T1r3,
and G-protein, a-gustducin, in isolated rat, mouse islets, and in INS-1
and MIN6 cells were analyzed using quantitative polymerase chain
reaction. Values are shown as the mean – standard error of the mean
(n = 3). (b) Portions of each extract in INS-1 cells were analyzed by
western blotting using specific antibodies against a-gustducin or
endogenous control proteins, including cytoplasm (Cyto; a-tubulin),
plasma membrane (Memb; E-cadherin) and nuclear soluble fraction
(Nuc; lamin A/C). The expression of a-gustducin in mouse tongue and
isolated mouse islets extracted by RIPA buffer was analyzed using
western blotting. (c) INS-1 cells were immunostained to detect
fluorescein isothiocyanate using anti-a-gustducin antibodies (green) and
insulin (red). The specificity of a-gustducin antibody was confirmed
using its blocking peptide (BP) in immunocytochemistry; the pre-
immune antibody showed no staining at the same concentrations
used in these experiments. mRNA, messenger ribonucleic acid; ND, not
detected; PBS, phosphate-buffered saline.
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Statistical analysis
The data are presented as the mean – standard error of the
mean. Statistical significance was determined using two-tailed
unpaired Student’s t-test. A two-way analysis of variance
(ANOVA) was carried out to analyze: (i) insulin secretion data
after a-gustducin knockdown and sucralose treatment; and (ii)
cAMP concentration data after a-gustducin knockdown and
measurement time.
RESULTS
Expression of taste receptor-related protein a-gustducin in
islets and pancreatic b-cells
To investigate whether taste receptors and a-gustducin are
involved in nutrition sensing in pancreatic b-cells, we first
examined mRNA expression of these molecules in rat and
mouse islets, and INS-1 and MIN6 cells. As a control, we also
measured taste receptors and a-gustducin expression in the
tongue tissue of each species. Quantitative polymerase chain
reaction results showed the expression of Tas1r3 and a-gust-
ducin in rat and mouse islets, and in INS-1 and MIN6 cells
(Figure 1a). Interestingly, a-gustducin and Tas1r3 expression in
rat islets was markedly higher than in the tongue. Expression
of Tas1r1 mRNA was detected in rat islets, INS-1 cells, rat ton-
gue, MIN6 cells and mouse tongue, but not in mouse islets.
Tas1r2 expression was detected only in the tongue tissue. Fur-
thermore, we examined a-gustducin protein expression by
western blot analysis in the cytoplasm, membrane or nuclear
extract of INS-1 cells, isolated mouse islets and mouse tongue.
The expression of a-gustducin protein was observed in the
cytoplasm and membrane fractions of INS-1 cells, mouse iso-
lated islets and mouse tongue (Figure 1b). Fluorescence
immunostaining showed that a-gustducin was localized in cyto-
plasm (Figure 1c). We carried out a-gustducin knockdown




























































































































































Figure 2 | Effect of a-gustducin knockdown on levels of cyclic adenosine monophosphate (cAMP), intracellular Ca2+ and insulin secretion in INS-1
cells. The expression of a-gustducin levels in INS-1 cells at 48 h after the transfection of a-gustducin small interfering ribonucleic acid (siRNA) was
examined by (a) quantitative polymerase chain reaction, (b) western blotting and (c) immunocytochemistry. Specific silencing was validated by at
least three independent experiments. Values are represented as the mean – standard error of the mean (n = 4). (d) Insulin secretion from INS-1
cells transfected with negative control siRNA (NC) or two kinds of a-gustducin siRNAs (Gust siRNA1 and Gust siRNA2) was measured after
treatment with 3 mmol/L glucose, 10 mmol/L glucose, 25 mmol/L glucose or 30 m/L KCl. The insulin secretion is shown as the percentage of
insulin content (secreted insulin / [intracellular insulin content + secreted insulin level]). (e) After transfection of negative control siRNA or a-
gustducin siRNA 2, insulin secretion was examined in INS-1 cells stimulated with 0.1 μmol/L epinephrine plus 3 mmol/L glucose. (f) cAMP in INS-1
cells, cultured in RPMI 1640, was measured after knockdown of a-gustducin. (g) Basal levels of intracellular free calcium [Ca2+]i were measured in
INS-1 cells transfected with Gust siRNA 1 or 2; (h) the average value. **P < 0.01 versus NC. Values are shown as the mean – standard error of the
mean (n = 3). mRNA, messenger ribonucleic acid; ND, not detected.
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a-gustducin siRNA led to a downregulation of a-gustducin
mRNA expression to approximately 10%, as compared with
the negative control siRNA (Figure 2a). Reduction in a-
gustducin protein levels by transfection of siRNA in INS-1 cells
was detected by western blotting and fluorescence immunos-
taining (Figure 2b,c).
Effect of a-gustducin knockdown on levels of cAMP,
intracellular Ca2+ and insulin secretion in INS-1 cells
We examined whether a reduction in expression of a-gustducin
affects insulin secretion from INS-1 cells. Interestingly, basal
insulin secretion from INS-1 cells, cultured with 3 mmol/L glu-
cose, was significantly increased by a-gustducin knockdown
compared with that in the control siRNA transfected cells (Fig-
ure 2d). However, insulin secretion was not affected by
10 mmol/L glucose, 25 mmol/L glucose or 30 mmol/L KCl
stimulation (Figure 2d). These results suggested that a-gust-
ducin is involved in basal, but not in high-glucose- or depolar-
ization-stimulated, insulin secretion by INS-1 cells. Next, we
determined whether a-gustducin knockdown mediated
enhancement of basal insulin secretion was caused by normal
exocytosis. Epinephrine stimulation has been reported to sup-
press insulin secretion by decreasing cAMP through the alpha-
2A-adrenoceptor22,23. Epinephrine stimulation completely abol-
ished the increase in basal insulin secretion by a-gustducin
knockdown (Figure 2e). Clapp et al. reported that a-gustducin
maintains a tonically low cAMP level in taste cells to ensure
adequate Ca2+ signaling24. As cAMP and [Ca2+]i are also criti-
cal for insulin secretion pathway in pancreatic b-cells, we spec-
ulated that a-gustducin plays an important role in the
regulation of basal insulin secretion by regulating cAMP and
calcium levels. First, we examined whether knockdown of a-
gustducin causes changes in cAMP concentration. As shown in
Figure 2f, the cAMP level in INS-1 cells was significantly
increased after a-gustducin knockdown compared with that in
cells treated with negative control siRNA. Thus, a-gustducin
was found to retain Ga-protein-specific functions in pancreatic
b-cells. The potentiation of insulin secretion by cAMP is strictly
dependent on the extracellular glucose concentration, and the
threshold is not reached at 3 mmol/L glucose. We measured
[Ca2+]i levels in INS-1 cells by a-gustducin knockdown. a-
Gustducin knockdown in INS-1 cells significantly increased the
amount of basal [Ca2+]i (Figure 2g,h). These results suggested
that the increase in basal insulin secretion in INS-1 cells by a-
gustducin knockdown was caused by an increase in [Ca2+]i
levels.
Expression of a-gustducin in HFD-fed mice and diabetic db/db
mice
a-Gustducin is expressed in INS-1 cells, and affects basal insu-
lin secretion by INS-1 cells. However, whether a-gustducin is
involved in the pathogenesis of diabetes is still unclear.
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Figure 3 | Expression and localization of a-gustducin (Gust) in high-fat diet-fed (HFD) mice and diabetic db/db mice. a-Gustducin was
immunostained using anti-gustducin antibodies to detect green fluorescent protein (green), insulin (red) and nuclei (Topro3 blue) in islets of (a)
4-week standard diet-fed mice (4 w STD) and 4-week HFD mice (4 w HFD) and (b) 52-week standard diet-fed mice (52 w STD), and (b) 52-week
HFD mice (52 w HFD). Decreasing expression of a-gustducin in the pancreas was observed in diabetic db/db mice compared with (c) 6-week-old
and (d) 12-week-old control db/m mice. Scale bar, 20 μm.
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Therefore, we examined changes in expression of a-gustducin
in diabetic db/db mice and HFD-fed mice. a-Gustducin was
weakly expressed in both STD-fed mice (4 weeks STD) and
HFD-fed mice islets (4 weeks HFD), and co-localized with
insulin (Figure 3a). A similar observation was made after com-
parison between 6-week-old and 12-week-old db/m mice (Fig-
ure 3c,d). In mice fed with HFD for 52 weeks, the expression
of a-gustducin in islets was reduced compared with that in 52-
week STD-fed mice (Figure 3b). In addition, in diabetic obesity
db/db mice, a-gustducin expression was decreased in pancreatic
islets compared with that in control db/m mice (Figure 3c,d).
These results suggested that the expression of a-gustducin in
pancreatic islets increases with age and decreased with HFD
feeding and obesity.
Involvement of a-gustducin in insulin secretion through the
sucralose–taste receptor axis
Although basal insulin secretion levels were enhanced by a-
gustducin knockdown in INS-1 cells, glucose-induced insulin
secretion was not significantly affected. To elucidate whether a-
gustducin is implicated in the detection of sweetness in pancre-
atic b-cells through taste receptors, we examined levels of basal
cAMP and basal insulin secretion under low glucose concentra-
tions induced by the taste signal agonist, sucralose, in pancre-
atic b-cells. cAMP levels were significantly increased after a-
gustducin knockdown in INS-1 cells treated with 10 mmol/L
sucralose in the presence of 3 mmol/L glucose (Figure 4a).
Two-way ANOVA showed a statistically significant interaction
between the effects of a-gustducin knockdown and sucralose
treatment time on cAMP (P < 0.001). Basal insulin secretion
by INS-1 cells was significantly enhanced by 10 mmol/L sucra-
lose treatment, but not by 1 mmol/L sucralose treatment (Fig-
ure 4b). Sucralose-stimulated insulin secretion was enhanced by
a-gustducin knockdown when compared with that in the con-
trol. However, two-way ANOVA showed no statistically significant
interaction between the effects of a-gustducin knockdown and
sucralose treatment on insulin secretion (P = 0.056). These
results suggest that a-gustducin is not mainly involved in the
sucralose–taste receptor signaling axis in the regulation of insu-
lin secretion.
Next, we investigated whether sucralose stimulation in islets
isolated from HFD mice with low a-gustducin expression
altered insulin secretion. As previously reported25,26,
16.7 mmol/L glucose stimulation of STD mouse islets signifi-
cantly increased the insulin secretion compared with 2.8 mmol/
L glucose, and this increase was attenuated with HFD exposure;
furthermore, GLP-1 stimulation did not increase basal insulin
secretion. Meanwhile, we found that sucralose-stimulated basal
insulin secretion was significantly increased in HFD mouse
islets compared with that in STD mouse islets (Figure 4c).
These results suggested that sucralose showed even larger


































































































Figure 4 | Functional role of a-gustducin (Gust) involved in the
sucralose–taste receptor signaling axis in pancreatic b-cells. (a) After
transfection of negative control (NC) small interfering ribonucleic acid
(siRNA) or two kinds of a-gustducin siRNAs, cyclic adenosine
monophosphate (cAMP) level was examined in INS-1 cells stimulated
with 10 mmol/L sucralose plus 3 mmol/L glucose. (b) After transfecting
with the negative control siRNA or two kinds of a-gustducin siRNAs,
insulin secretion was examined in INS-1 cells treated with 3 mmol/L
glucose (G3), 1 mmol/L sucralose plus 3 mmol/L glucose (Su; 1 mmol/
L) or 10 mmol/L sucralose plus 3 mmol/L glucose (Su 10 mmol/L).
*P < 0.05 versus NC. **P < 0.01 versus NC. Values are shown as
mean – standard error of the mean (n = 4). (c) Insulin secretion from
isolated islets from mice fed a standard diet (STD) and high-fat diet
(HFD) was measured after treating with 2.8 mmol/L glucose
(G2.8 mmol/L), G2.8 + 0.1 µmol/L glucagon-like peptide-(GLP-1),
G2.8 + 10 mmol/L sucralose and 16.7 mmol/L glucose. *P < 0.05
versus STD. **P < 0.01 versus STD. Values are shown as the
mean – standard error of the mean (n = 3).
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expression (Figure 3b,d). These results collectively suggested
that a-gustducin is involved in insulin secretion in mouse pan-
creatic islets through signaling pathways independent of the
taste receptor.
DISCUSSION
In the present study, we showed the expression of the taste sig-
naling-related G-protein, a-gustducin, in both mouse islets and
the rat pancreatic b-cell line, INS-1, and examined its role in
insulin secretion after knockdown experiments in INS-1 cells.
Although a-gustducin did not play a major role in glucose- or
depolarization-stimulated insulin secretion in INS-1 cells, three
interesting observations were made in this study. First, basal
insulin secretion, cAMP levels and [Ca2+]i levels were signifi-
cantly increased after a-gustducin knockdown in INS-1 cells
(Figure 2d–h). The a2 adrenoceptor is coupled with inhibitory
G protein and is known to decrease the second messenger
cAMP27. The results of stimulation with epinephrine, an a2-
adrenoceptor agonist (Figure 2e) suggested that the increase in
basal insulin secretion due to a-gustducin knockdown was not
a result of protein leakage, but due to a change in the exocyto-
sis signal. The negative regulation of basal cAMP levels by a-
gustducin in INS-1 cells is consistent with the report that the
taste cells of a-gustducin-knockout mice show an elevated basal
cAMP level24. The suppression of a-gustducin in INS-1 cells
significantly increased the basal [Ca2+]i levels, indicating that in
the basal state, a-gustducin contributes to maintain cAMP and
[Ca2+]i at low levels. Second, a-gustducin expressed in mouse
pancreatic islets was co-localized with insulin, and the expres-
sion levels of a-gustducin were decreased in HFD-fed mice and
diabetic db/db mice (Figure 4). db/db mice at 6–8 weeks-of-age
usually present hyperinsulinemia and hyperlipidemia28. At 10–
14 weeks-of-age, the db/db mice became fully diabetic with sig-
nificantly higher plasma glucose levels28. We observed that the
expression of a-gustducin decreased in 6-week-old or 12-week-
old db/db mice. Thus, decreased a-gustducin expression levels
are speculated to be involved in b-cell dysfunction and the
early phase of type 2 diabetes. Third, basal insulin secretion
showed no statistically significant correlation with the effects of
a-gustducin knockdown and sucralose treatment on insulin
secretion (P = 0.056). These results suggest that a-gustducin is
not involved in the sucralose–taste receptor signaling axis in
pancreatic b-cells.
Previously, Nakagawa et al.11 reported sucralose-stimulated
insulin secretion in the mouse pancreatic b-cell line, MIN6, due
to higher cAMP and Ca2+ levels. They concluded that these
effects of sucralose were, at least partially, mediated by the het-
erodimer of T1r2 and T1r3, the sweet receptor found in taste
cells. Furthermore, Nakagawa et al. showed that expression
levels of a-gustducin were extremely low in MIN6 cells, and
that a-gustducin knockdown did not affect [Ca2+]i responses to
various artificial sweeteners12. Some differences of their results
and the present results could be explained either by species dif-
ference (between mice and rats) or by the difference between
tumor cell lines. We confirmed high expression of a-gustducin,
Tas1r1, Tas1r2 and Tas1r3 mRNA in rat islets as positive con-
trols, but exact reasons for apparent discrepancies between the
findings of Nakagawa et al. and the present study regarding
the roles of a-gustducin in insulin secretion remain unknown.
Interestingly, sucralose increased basal insulin secretion even in
cellular states with abnormal glucose responsiveness after HFD
challenge. In order to determine how this affects damaged b-
cells, further studies are necessary.
The previous studies investigated different b-cell lines; the
expression of T1r2 mRNA was not detected in the INS-1 cells
used by us, and the classical sweet receptor–a-gustducin path-
way (mediated by T1r2 + T1r3) involved in insulin secretion
might be absent from INS-1 cells. Therefore, taken together, a-
gustducin might couple with other G protein-coupled receptors,
in addition to the classical taste receptor, T1r3. Currently, we
do not know which receptors couple with a-gustducin and
mediate the effect of insulin secretion in INS-1 cells. Nakagawa
et al. suggested that T1r3 acts as a homodimer; however, its
association with a-gustducin is not yet clear29. We were not
able to verify the association between a-gustducin and T1r3 in
INS-1 cells, because we could not silence the T1r3 gene in INS-
1 cells. We observed that certain subtypes of T1rs (Figure 1a)
and T2rs (data not shown) were expressed in INS-1 cells, in
which T1r2 was absent. The types of extracellular factors that
couple with a-gustducin in b-cells are yet to be explored. In
taste cells, sweet compounds bind to and activate specific
G protein-coupled receptors that interact with a-gustducin,
Gb3 and Gc13
4,30. The present data showed that during sucra-
lose-stimulated insulin secretion, sucralose is not absorbed from
the intestine31, and does not affect b-cells directly in vivo.
Wong et al.32 reported that a-gustducin knockout mice showed
reduced response to bitter, sweet and umami stimuli. We
examined whether a-gustducin participates in insulin secretion
stimulated by possible taste receptor ligands other than glucose
and sweeteners. Although various substances, such as fructose,
denatonium, leucine and monosodium glutamate, and the hor-
mones, GLP-1 and glucagon, induced insulin secretion in INS-
1 cells, the effects of a-gustducin knockdown on insulin secre-
tion were not significant (data not shown). However, Kyriazis
et al.14 showed that ablation of sweet taste receptor protein,
T1r2, obliterates fructose-induced calcium responses and insulin
release in the mouse pancreatic b-cell line, MIN6, and mouse
islets. In addition, taste receptor complexes of T1r1 and T1r3
regulate the amino acid-induced insulin secretion in the mouse
pancreatic b-cell line, MIN613. Li et al.33 showed that a-gust-
ducin coupled with the fatty acid receptor in the colon. Taken
together, a-gustducin is speculated to be associated with amino
acid or fatty acid signaling in pancreatic b-cells. Further studies
are required to identify the ligands and/or receptors that acti-
vate a-gustducin in in vivo.
At the basal state, a-gustducin maintains tonically low cAMP
level and insulin secretion in INS-1 cells. It has been reported
that cAMP exerts pleiotropic effects and is important not only
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for insulin secretion, but also for b-cell proliferation or survival.
It would be interesting to explore the possible role of a-gust-
ducin in this respect.
In conclusion, a-gustducin is expressed in rat and mouse
islets, and in INS-1 cells and MIN6 cells, and negatively regu-
lates [Ca2+]i and cAMP levels, and insulin secretion in INS-1
cells. The present results show a potential role for a-gustducin
and a novel mechanism regulating insulin secretion in pancre-
atic b-cells. Furthermore, the change in a-gustducin expression
indicates its role in the development of type 2 diabetes, because
expression of a-gustducin is reduced in pancreatic islets of
HFD-fed mice and diabetic db/db mice. Further in vivo studies
could elucidate the significance of these findings in normal
physiology, as well as in pathological states, such as diabetes
mellitus.
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